- Email: [email protected]
Cloned DNA sequence coding for tetanus toxin or its fragments containing an epitope used to express antigens for vaccine production
indigenous protein (I) and comprising a recombinantly produced immunogenic form of (I) is described. The vaccine may comprise (a) a multimer consisting of at least two repeating units of at least one epitope of (I); (b) at least one epitope of (I) conjugated to a nonbacterial polypeptide, or (c) a multimer consisting of at least two repeating units of at least one epitope of (I) conjugated to an additional polypeptide sequence. The D N A sequence encoding the immunogenic form of (I) as defined is described, together with host cells transformed with the D N A sequence. A vaccine effective against mammalian fertility comprises a vaccinia virus genome containing a D N A sequence of formula (Hormone)n, where n is 1-20, and Hormone is a D N A sequence derived from the sequence encoding a reproductive hormone. The vaccines neutralize the effects of indigenous (I) and can be made species-specific or can have cross-species effectiveness. They may be used for the control of fertility in humans and other mammals. (I) Is e.g. LH or FSH. 066-87
Tick vaccine especially useful against Boophilus microplus comprises antigenic material derived from the tick synganglion
Cloned DNA sequence coding for tetanus toxin or its fragments containing an epitope used to express antigens for vaccine production
Wellcome Eur. 209 281; January 1987 A cloned D N A sequence (I) encoding tetanus toxin (TT) or a fragment of TI', preferably the B or C fragment or the heavy or light chains of TI', is new. A culture of Clostridium tetani is lysed, the TT frament C isolated and its N-terminal sequence determined. A series of oligonucleotides is synthesized to correspond to possible D N A coding sequences and used to probe a total digest of C. tetani genomic DNA. D N A fragments of approximately the correct mol. wt are cloned, e.g. in plasmid pAT153, and the recombinant products used to transform Escherichia coli JM101 cells. Colonies are tested for hybridization with the probes to identify a set of clones coding for the entire TT sequence. The D N A sequence can be inserted in the correct reading frame into an E. coli gene to express a fusion protein. These protein can then be split enzymatically or chemically. Alternatively, non-pathogenic viruses, e.g. thymidine-kinase deficient vaccina virus, can be used as the host. TT or its fragments are useful in tetanus vaccine production. 069-87
Coopers Anim. Health Aust. Eur. 208 507; 14 January 1987 An antigenic composition comprises antigenic material derived from the synganglion of a tick, optionally with a saponin as an adjuvant. The composition may also contain antigenic material derived from the gut of the tick. The vaccine may be used for control of Argasid and Ixodid ticks, including Boophilus, Rhipicephalus, Ixodes, Hyalomma, Amblyomma, Dermacentor and Heamaphysalis spp. The vaccine gives long periods of protection. In a preferred aspect of the invention, the antigenic materials are obtained from larval ticks by grinding or homogenizing etc., followed by extraction with a suitable aq. medium, fractionation using affinity, gel permeation, ion-exchange, and hydrophobic gel chromatography, electrophoresis, electrofocussing, selective precipitation and concentration. The antigenic materials may also be obtained by cloning and expression of tick genetic material in suitable host organisms, e.g. bacteria. The antigenic materials may also be obtained by in vitro culture of tick cells or tick cells hybridized with other animal cells. 06%87
Complete nucleotide sequence of cattle diarrhoea virus genome useful for producing antigenic proteins for vaccines and diagnostic preparations; gene cloning and expression in
Escherichia coli
Oral vaccine for immunization against enteric disease-genetic hybrid derivative of an attenuated galactose-epimeraselacking strain of Salmonella typhi
US Seer. Army US 4632 830; 30 December 1986 A live, attenuated, oral vaccine system is described for immunization against enteric disease. This oral vaccine is a genetic hybrid derivative of an attenuated galactose-epimerase-lacking strain of Salmonella typhi which carries at least one protective antigen other than normal somatic S. typhi antigens. The vaccine can provide protection against both typhoid fever and at least one other enteric disease. A bivalent oral vaccine is described wherein the non-typhoid protective antigen is the plasmid-encoded form I antigen of Shigella sonnei. A protective antigen from S. sonnei was transferred to a streptomycin-resistant mutant of S. typhi strain Ty21a. The transconjugant S. typhi strain expressed both S. typhi and S. sonnei antigens and protected experimental animals against lethal infections with S. typhi or S. sonneL The strain is useful as a vaccine against typhoid fever and bacillary dysentery caused by S. sonnei. 070-87 Live vaccine for protecting animals against rabies containing a stable variant of Street Alabama Dufferin virus
Reg. Wallone; Chiron.
Behringwerke
Eur. 208 672; 14 January 1987
Eur. 210 522; 4 January 1987
The nucleotide sequence (I) of the cattle diarrhoea virus (BDV) genome is described. The sequence contains over 12 400 bases. The specification also describes: (1) portions of sequence (I); (2) recombinant expression systems able to produce a BDV-related protein (II) containing D N A derived from (I); (3) vectors and transformed microorganisms containing this expression system; (4) proteins produced by such microorganisms; (5) particles immunogenic against BDV containing a neutralizing epitope and a particle-forming polypeptide sequence, and (6) vaccines containing (II). (II) Are useful in vaccines to protect cattle and pigs against BDV, and can also be used to raise antibodies useful in diagnosis and passive immunotherapy. D N A / R N A sequences are useful as diagnostic probes. R N A isolated from virus cultured on embryonic kidney cells was used to prepare a e D N A library from which 10 clones representing overlapping segments of the genome were obtained. These were mapped and sequenced. Portions of the genome were ligated into vectors and expressed in Escherichia coil 068-87
Living vaccine for immunization of animals against rabies contains a variant of SAD (Street Alabama Dufferin) virus which retains its activity for at least 3 days at 20°C. Variant VA1 (CNCM 1-430) is isolated from the BSR-19 strain by cloning on soft agar. Variants VA12 (I-431) or VA17 (I-432) are recovered using the monoclonal antibody MW-187.2.8, while variant VA20 is isolated from VA12 using monoclonal antibody PM13. The variant is grown on the cell line BHK-BSR in monolayers in several stages at a split rate of 1 : 3-10. Every 2-5 days virus is harvested and stored at -20 to -80°C. The resulting virus suspension is made into a vaccine with e.g. pH 7.2 buffer, bovine serum albumin and ovalbumin. The variants are apathogenic in adult mice when administered intracerebrally and remain so after intercerebral passages in baby mice. The vaccine can be given parenterally or orally, especially to dogs and foxes. The strains are harmless to animals. They are genetically stable, well defined and identifiable from wild strains, and are stable over long periods at variable temperature. 071-87
250 Vaccine, Vol. 5, September 1987
Tick vaccine especially useful against Boophilus microplus comprises antigenic material derived from the tick synganglion
Cloned DNA sequence coding for tetanus toxin or its fragments containing an epitope used to express antigens for vaccine production
Wellcome Eur. 209 281; January 1987 A cloned D N A sequence (I) encoding tetanus toxin (TT) or a fragment of TI', preferably the B or C fragment or the heavy or light chains of TI', is new. A culture of Clostridium tetani is lysed, the TT frament C isolated and its N-terminal sequence determined. A series of oligonucleotides is synthesized to correspond to possible D N A coding sequences and used to probe a total digest of C. tetani genomic DNA. D N A fragments of approximately the correct mol. wt are cloned, e.g. in plasmid pAT153, and the recombinant products used to transform Escherichia coli JM101 cells. Colonies are tested for hybridization with the probes to identify a set of clones coding for the entire TT sequence. The D N A sequence can be inserted in the correct reading frame into an E. coli gene to express a fusion protein. These protein can then be split enzymatically or chemically. Alternatively, non-pathogenic viruses, e.g. thymidine-kinase deficient vaccina virus, can be used as the host. TT or its fragments are useful in tetanus vaccine production. 069-87
Coopers Anim. Health Aust. Eur. 208 507; 14 January 1987 An antigenic composition comprises antigenic material derived from the synganglion of a tick, optionally with a saponin as an adjuvant. The composition may also contain antigenic material derived from the gut of the tick. The vaccine may be used for control of Argasid and Ixodid ticks, including Boophilus, Rhipicephalus, Ixodes, Hyalomma, Amblyomma, Dermacentor and Heamaphysalis spp. The vaccine gives long periods of protection. In a preferred aspect of the invention, the antigenic materials are obtained from larval ticks by grinding or homogenizing etc., followed by extraction with a suitable aq. medium, fractionation using affinity, gel permeation, ion-exchange, and hydrophobic gel chromatography, electrophoresis, electrofocussing, selective precipitation and concentration. The antigenic materials may also be obtained by cloning and expression of tick genetic material in suitable host organisms, e.g. bacteria. The antigenic materials may also be obtained by in vitro culture of tick cells or tick cells hybridized with other animal cells. 06%87
Complete nucleotide sequence of cattle diarrhoea virus genome useful for producing antigenic proteins for vaccines and diagnostic preparations; gene cloning and expression in
Escherichia coli
Oral vaccine for immunization against enteric disease-genetic hybrid derivative of an attenuated galactose-epimeraselacking strain of Salmonella typhi
US Seer. Army US 4632 830; 30 December 1986 A live, attenuated, oral vaccine system is described for immunization against enteric disease. This oral vaccine is a genetic hybrid derivative of an attenuated galactose-epimerase-lacking strain of Salmonella typhi which carries at least one protective antigen other than normal somatic S. typhi antigens. The vaccine can provide protection against both typhoid fever and at least one other enteric disease. A bivalent oral vaccine is described wherein the non-typhoid protective antigen is the plasmid-encoded form I antigen of Shigella sonnei. A protective antigen from S. sonnei was transferred to a streptomycin-resistant mutant of S. typhi strain Ty21a. The transconjugant S. typhi strain expressed both S. typhi and S. sonnei antigens and protected experimental animals against lethal infections with S. typhi or S. sonneL The strain is useful as a vaccine against typhoid fever and bacillary dysentery caused by S. sonnei. 070-87 Live vaccine for protecting animals against rabies containing a stable variant of Street Alabama Dufferin virus
Reg. Wallone; Chiron.
Behringwerke
Eur. 208 672; 14 January 1987
Eur. 210 522; 4 January 1987
The nucleotide sequence (I) of the cattle diarrhoea virus (BDV) genome is described. The sequence contains over 12 400 bases. The specification also describes: (1) portions of sequence (I); (2) recombinant expression systems able to produce a BDV-related protein (II) containing D N A derived from (I); (3) vectors and transformed microorganisms containing this expression system; (4) proteins produced by such microorganisms; (5) particles immunogenic against BDV containing a neutralizing epitope and a particle-forming polypeptide sequence, and (6) vaccines containing (II). (II) Are useful in vaccines to protect cattle and pigs against BDV, and can also be used to raise antibodies useful in diagnosis and passive immunotherapy. D N A / R N A sequences are useful as diagnostic probes. R N A isolated from virus cultured on embryonic kidney cells was used to prepare a e D N A library from which 10 clones representing overlapping segments of the genome were obtained. These were mapped and sequenced. Portions of the genome were ligated into vectors and expressed in Escherichia coil 068-87
Living vaccine for immunization of animals against rabies contains a variant of SAD (Street Alabama Dufferin) virus which retains its activity for at least 3 days at 20°C. Variant VA1 (CNCM 1-430) is isolated from the BSR-19 strain by cloning on soft agar. Variants VA12 (I-431) or VA17 (I-432) are recovered using the monoclonal antibody MW-187.2.8, while variant VA20 is isolated from VA12 using monoclonal antibody PM13. The variant is grown on the cell line BHK-BSR in monolayers in several stages at a split rate of 1 : 3-10. Every 2-5 days virus is harvested and stored at -20 to -80°C. The resulting virus suspension is made into a vaccine with e.g. pH 7.2 buffer, bovine serum albumin and ovalbumin. The variants are apathogenic in adult mice when administered intracerebrally and remain so after intercerebral passages in baby mice. The vaccine can be given parenterally or orally, especially to dogs and foxes. The strains are harmless to animals. They are genetically stable, well defined and identifiable from wild strains, and are stable over long periods at variable temperature. 071-87
250 Vaccine, Vol. 5, September 1987